Sean M Mccarthy

US Patent:

20030069196, Apr 10, 2003

Filed:

Dec 4, 2001

Appl. No.:

10/004633

Inventors:

Douglas Levinson - Sherborn MA, US
Clare Lloyd - London, GB
Sean McCarthy - San Diego CA, US

Assignee:

Millennium Pharmaceuticals, Inc.

International Classification:

A61K048/00
C07H021/04

US Classification:

514/044000, 536/023200

Abstract:

The present invention relates to methods and compositions for the treatment and diagnosis of immune disorders, especially T helper lymphocyte-related disorders, and also for the treatment of mast cell-related processes and disorders, ischemic disorders and injuries, including ischemic renal disorders and injuries. For example, genes which are differentially expressed within and among T helper (TH) cells and TH cell subpopulations, which include, but are not limited to TH0, TH1 and TH2 cell subpopulations are identified. Genes are also identified via the ability of their gene products to interact with gene products involved in the differentiation, maintenance and effector function of such TH cells and TH cell subpopulations. The genes identified can be used diagnostically or as targets for therapeutic intervention. In this regard, the present invention provides methods for the identification and therapeutic use of compounds as treatments of immune disorders, especially TH cell subpopulation-related disorders. Additionally, methods are provided for the diagnostic evaluation and prognosis of TH cell subpopulation-related disorders, for the identification of subjects exhibiting a predisposition to such conditions, for monitoring patients undergoing clinical evaluation for the treatment of such disorders, and for monitoring the efficacy of compounds used in clinical trials. Methods are also provided for the treatment of symptoms associated with mast cell-related processes or disorders and ischemic disorders and injuries using the genes, gene products and antibodies of the invention.

US Patent:

20050119209, Jun 2, 2005

Filed:

May 3, 2004

Appl. No.:

10/838852

Inventors:

Douglas Levinson - Sherborn MA, US
Clare Lloyd - London, GB
Sean McCarthy - Boston MA, US

International Classification:

A61K048/00
C07H021/04

US Classification:

514044000, 536023200

Abstract:

The present invention relates to methods and compositions for the treatment and diagnosis of immune disorders, especially T helper lymphocyte-related disorders, and also for the treatment of mast cell-related processes and disorders, ischemic disorders and injuries, including ischemic renal disorders and injuries. For example, genes which are differentially expressed within and among T helper (TH) cells and TH cell subpopulations, which include, but are not limited to TH0, TH1 and TH2 cell subpopulations are identified. Genes are also identified via the ability of their gene products to interact with gene products involved in the differentiation, maintenance and effector function of such TH cells and TH cell subpopulations. The genes identified can be used diagnostically or as targets for therapeutic intervention. In this regard, the present invention provides methods for the identification and therapeutic use of compounds as treatments of immune disorders, especially TH cell subpopulation-related disorders. Additionally, methods are provided for the diagnostic evaluation and prognosis of TH cell subpopulation-related disorders, for the identification of subjects exhibiting a predisposition to such conditions, for monitoring patients undergoing clinical evaluation for the treatment of such disorders, and for monitoring the efficacy of compounds used in clinical trials. Methods are also provided for the treatment of symptoms associated with mast cell-related processes or disorders and ischemic disorders and injuries using the genes, gene products and antibodies of the invention.

US Patent:

20090041752, Feb 12, 2009

Filed:

Jul 31, 2007

Appl. No.:

11/888354

Inventors:

Douglas Adam Levinson - Sherborn MA, US
Clare M. Lloyd - London, GB
Sean A. McCarthy - San Diego CA, US

International Classification:

A61K 39/395
A61K 38/00
A61P 9/00

US Classification:

4241301, 514 2, 514 12

Abstract:

The present invention relates to methods and compositions for the treatment and diagnosis of immune disorders, especially T helper lymphocyte-related disorders, and also for the treatment of mast cell-related processes and disorders, ischemic disorders and injuries, including ischemic renal disorders and injuries. For example, genes which are differentially expressed within and among T helper (TH) cells and TH cell subpopulations, which include, but are not limited to TH0, TH1 and TH2 cell subpopulations are identified. Genes are also identified via the ability of their gene products to interact with gene products involved in the differentiation, maintenance and effector function of such TH cells and TH cell subpopulations. The genes identified can be used diagnostically or as targets for therapeutic intervention. In this regard, the present invention provides methods for the identification and therapeutic use of compounds as treatments of immune disorders, especially TH cell subpopulation-related disorders. Additionally, methods are provided for the diagnostic evaluation and prognosis of TH cell subpopulation-related disorders, for the identification of subjects exhibiting a predisposition to such conditions, for monitoring patients undergoing clinical evaluation for the treatment of such disorders, and for monitoring the efficacy of compounds used in clinical trials. Methods are also provided for the treatment of symptoms associated with mast cell-related processes or disorders and ischemic disorders and injuries using the genes, gene products and antibodies of the invention.

US Patent:

20110123548, May 26, 2011

Filed:

Mar 23, 2010

Appl. No.:

12/729438

Inventors:

Douglas Adam Levinson - Sherborn MA, US
Clare M. Lloyd - London, GB
Sean A. McCarthy - Chapel Hill NC, US

Assignee:

Millennium Pharmaceuticals, Inc. - Cambridge MA

International Classification:

A61K 39/395
A61K 38/17
A61K 48/00
A61P 9/10
A61P 13/12

US Classification:

4241721, 514 154, 514 212, 514 44 R

Abstract:

The present invention relates to methods and compositions for the treatment and diagnosis of immune disorders, especially T helper lymphocyte-related disorders, and also for the treatment of mast cell-related processes and disorders, ischemic disorders and injuries, including ischemic renal disorders and injuries. For example, genes which are differentially expressed within and among T helper (TH) cells and TH cell subpopulations, which include, but are not limited to TH0, TH1 and TH2 cell subpopulations are identified. Genes are also identified via the ability of their gene products to interact with gene products involved in the differentiation, maintenance and effector function of such TH cells and TH cell subpopulations. The genes identified can be used diagnostically or as targets for therapeutic intervention. In this regard, the present invention provides methods for the identification and therapeutic use of compounds as treatments of immune disorders, especially TH cell subpopulation-related disorders. Additionally, methods are provided for the diagnostic evaluation and prognosis of TH cell subpopulation-related disorders, for the identification of subjects exhibiting a predisposition to such conditions, for monitoring patients undergoing clinical evaluation for the treatment of such disorders, and for monitoring the efficacy of compounds used in clinical trials. Methods are also provided for the treatment of symptoms associated with mast cell-related processes or disorders and ischemic disorders and injuries using the genes, gene products and antibodies of the invention.

US Patent:

20120171204, Jul 5, 2012

Filed:

Jun 23, 2011

Appl. No.:

13/166982

Inventors:

Douglas Adam Levinson - Sherborn MA, US
Clare M. Lloyd - London, GB
Sean A. McCarthy - Chapel Hill NC, US

Assignee:

Millennium Pharmaceuticals, Inc. - Cambridge MA

International Classification:

A61K 39/395
A61P 11/06
A61P 37/08
A61P 27/02
G01N 33/53
A61P 31/08
C07K 19/00
C12Q 1/68
G01N 21/64
A61P 37/00
A61P 33/02

US Classification:

4241341, 5303873, 435 612, 435 71, 435 792

Abstract:

The present invention relates to methods and compositions for the treatment and diagnosis of immune disorders, especially T helper lymphocyte-related disorders, and also for the treatment of mast cell-related processes and disorders, ischemic disorders and injuries, including ischemic renal disorders and injuries. For example, genes which are differentially expressed within and among T helper (TH) cells and TH cell subpopulations, which include, but are not limited to TH0, TH1 and TH2 cell subpopulations are identified. Genes are also identified via the ability of their gene products to interact with gene products involved in the differentiation, maintenance and effector function of such TH cells and TH cell subpopulations. The genes identified can be used diagnostically or as targets for therapeutic intervention. In this regard, the present invention provides methods for the identification and therapeutic use of compounds as treatments of immune disorders, especially TH cell subpopulation-related disorders. Additionally, methods are provided for the diagnostic evaluation and prognosis of TH cell subpopulation-related disorders, for the identification of subjects exhibiting a predisposition to such conditions, for monitoring patients undergoing clinical evaluation for the treatment of such disorders, and for monitoring the efficacy of compounds used in clinical trials. Methods are also provided for the treatment of symptoms associated with mast cell-related processes or disorders and ischemic disorders and injuries using the genes, gene products and antibodies of the invention.

US Patent:

20180330813, Nov 15, 2018

Filed:

Apr 5, 2018

Appl. No.:

15/946218

Inventors:

- Worcester MA, US
Logan M. Garber - Southborough MA, US
Sean M. McCarthy - Charlton MA, US
Scott G. Pilate - Sturbridge MA, US

International Classification:

G16H 40/20
G16H 10/60
G08B 5/36

Abstract:

A patient treatment status notification system in a healthcare facility with multiple examination rooms includes a first electronic visual status indicator and a second electronic visual status indicator to be installed outside a first examination room, an indicator control circuit configured to communicate with and control the first and second electronic visual status indicators of the first examination room, a manual input device for the first examination room configured to receive user input representing change of a treatment status of a patient assigned to the first examination room, a switch multiplexer configured to communicate with and receive the user input from the manual input device for the first examination room, and a central control processor coupled to the indicator control circuit and the switch multiplexer to update the treatment status of the first examination room.